JP2017520554A5 - - Google Patents

Download PDF

Info

Publication number
JP2017520554A5
JP2017520554A5 JP2016574360A JP2016574360A JP2017520554A5 JP 2017520554 A5 JP2017520554 A5 JP 2017520554A5 JP 2016574360 A JP2016574360 A JP 2016574360A JP 2016574360 A JP2016574360 A JP 2016574360A JP 2017520554 A5 JP2017520554 A5 JP 2017520554A5
Authority
JP
Japan
Prior art keywords
seq
pharmaceutical composition
colitis
composition according
ox1r
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016574360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017520554A (ja
JP6697403B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/064028 external-priority patent/WO2015197572A1/en
Publication of JP2017520554A publication Critical patent/JP2017520554A/ja
Publication of JP2017520554A5 publication Critical patent/JP2017520554A5/ja
Application granted granted Critical
Publication of JP6697403B2 publication Critical patent/JP6697403B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016574360A 2014-06-24 2015-06-23 炎症性腸疾患の処置のための方法及び医薬組成物 Expired - Fee Related JP6697403B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305990 2014-06-24
EP14305990.5 2014-06-24
PCT/EP2015/064028 WO2015197572A1 (en) 2014-06-24 2015-06-23 Pharmaceutical compositions comprising agonists of orexin-1 receptor ox1r for the treatment of inflammatory bowel diseases

Publications (3)

Publication Number Publication Date
JP2017520554A JP2017520554A (ja) 2017-07-27
JP2017520554A5 true JP2017520554A5 (enExample) 2018-08-02
JP6697403B2 JP6697403B2 (ja) 2020-05-20

Family

ID=51062760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016574360A Expired - Fee Related JP6697403B2 (ja) 2014-06-24 2015-06-23 炎症性腸疾患の処置のための方法及び医薬組成物

Country Status (5)

Country Link
US (1) US10172921B2 (enExample)
EP (1) EP3169348B1 (enExample)
JP (1) JP6697403B2 (enExample)
ES (1) ES2742179T3 (enExample)
WO (1) WO2015197572A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017064302A1 (en) * 2015-10-16 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
CA3003283A1 (en) * 2015-11-24 2017-06-01 Theravance Biopharma R&D Ip, Llc Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
EP3454857A1 (en) * 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
EP4097119B1 (en) 2020-01-31 2025-05-07 The Johns Hopkins University Bile acid-gcpii inhibitor conjugates to treat inflammatory diseases
WO2021156310A1 (en) * 2020-02-04 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Tafa4 polypeptide or polynucleotide for treating inflammatory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000787A2 (en) 1999-06-25 2001-01-04 Smithkline Beecham Corporation Methods of treatment using lig 72a and variants thereof
WO2004082715A1 (ja) * 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
KR20100057063A (ko) * 2007-09-11 2010-05-28 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드의 용도

Similar Documents

Publication Publication Date Title
Czoty et al. Evaluation of the “pipeline” for development of medications for cocaine use disorder: a review of translational preclinical, human laboratory, and clinical trial research
MA38261A1 (fr) Composes comprenant un noyau polycyclique destines a etre utilises dans le traitement de l'hepatite c (vhc)
WO2017081211A3 (en) Antigen-binding polypeptides directed against cd38
Sharma et al. Common biological mechanisms between bipolar disorder and type 2 diabetes: focus on inflammation
NZ734019A (en) Novel micro-dystrophins and related methods of use
MA44119A (fr) Vecteurs viraux adéno-associés à utiliser dans le traitement de l'amyotrophie spinale
EP3870030A4 (en) SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS
EP4364804A3 (en) Inhibitors of keap1-nrf2 protein-protein interaction
EP3376939A4 (en) AUTOMATIC PROCEDURE FOR THE OBJECTIVE QUANTIFICATION OF RETAIL PROPERTIES BY RETIREMENT REGION AND DIAGNOSIS OF RETAIL SKIN PATHOLOGY
EP3498279A4 (en) PHARMACEUTICAL COMPOSITION WITH AMODIAQUIN AND ANTIDIABETIC MEDICINAL PRODUCT AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING DIABETES
WO2014197816A8 (en) Stimulus responsive nanocomplexes and methods of use thereof
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2015158890A3 (en) Pancreatic cancer therapy and diagnosis
ZA202409847B (en) Gastro-resistant controlled release oral dosage forms
BR112014011758A2 (pt) composição farmacêutica, proteína de fusão, polinucleotídeo, vetor, célula isolada, métodos para produzir uma proteína de fusão, para tratar ou previnir uma doença ou condição, para diagnosticar a suscetibilidade de um indivíduo a desenvolver uma doença ou condição, para determinar uma adequabilidade do indivíduo para ingressar em um experimento de classificação dedroga, e para identificar um agente, uso de uma combinação, e, combinação.
WO2012007913A3 (en) Oral administration forms for controlled release of rifampicin or other antibiotics for the treatment of bacterial infections and inflammatory diseases of the gastrointestinal tract
WO2017069288A8 (en) Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof
WO2016050835A3 (en) Selective inhibitors of neutrophil elastase for treating neuropathic pain and chronic pain states harbouring a neuropathic component
MA39912B1 (fr) Dérivés de 2-aryl-4-hydroxy-1,3-thiazole comme antagonistes du trpm8, et leur utilisation dans le traitement de la neuralgie, de la douleur, de la bpco et de l'asthme.
Riehle et al. What's in an item? Predicting social outcomes in schizophrenia spectrum disorders from the PANSS item" Poor Rapport"
WO2013111014A3 (en) Methods and compositions for treating neuron loss in inflammatory bowel disease
WO2017095918A3 (en) Methods for treating cancer using rspo3 antagonists
Cipolla et al. Comment on: inhaled antimicrobial therapy--barriers to effective treatment, by J. Weers, inhaled antimicrobial therapy-barriers to effective treatment, Adv. Drug Deliv. Rev.(2015), http://dx. doi. org/10.1016/j. addr. 2014.08. 013
YU et al. Resistance of E. coli from fur-bearing animals to fluoroquinolones and compound Chinese medicine [J]
Schaumburg et al. Is Africa the origin of major Haitian Staphylococcus aureus lineages?